Emerging Gene Therapies and Targeted Agents for Patients with Hemophilia
Please use the box in the top-right corner of the screen to login or register.
Release Date: July 29, 2022
Expiration Date: July 29, 2023
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
Join Dr. Pipe as he outlines new innovations and findings relative to hemophilia A and B. Topics include gene therapy, anti-tissue factor pathway inhibitors, and other exciting developments in hemophilia.
This activity is designed for healthcare professionals who treat and manage patients with hemophilia.
Upon completion of this educational activity, participants should be able to:
- Evaluate currently published data on gene therapy for hemophilia
- Differentiate emerging therapeutics based on an understanding of the mechanism of action, safety, and efficacy in ongoing clinical trials
Emerging Gene Therapies and Targeted Agents for Patients with Hemophilia – Steven W. Pipe, MD
Instructions for Participation and Credit
This activity is eligible for credit through July 29, 2023. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Steven W. Pipe, MD
Laurence A. Boxer Research Professor of Pediatrics
Professor of Pathology
University of Michigan
Ann Arbor, Michigan
Dr. Steven Pipe received his medical training at the University of Toronto. He completed his pediatric residency/chief residency at McMaster University Medical Centre, Ontario, and his fellowships at the University of Michigan, Ann Arbor. Dr. Pipe is a Professor and the Laurence A. Boxer Research Professor of Pediatrics and Professor of Pathology at the University of Michigan. In addition he is the Medical Director of the Pediatric Hemophilia and Coagulation Disorders Program and Medical Director of the Special Coagulation Laboratory.
Dr. Pipe has served on the Board of Directors for the Hemostasis and Thrombosis Research Society, as Chair of the Board of Directors for the American Thrombosis and Hemostasis Network, and most recently as Chair of the Medical and Scientific Advisory Council to the National Hemophilia Foundation. His clinical interests include bleeding and thrombotic disorders and congenital vascular anomalies. Dr Pipe also directs a basic research lab investigating coagulation factor VIII and the molecular mechanisms of hemophilia A. He has been actively involved in clinical trials with novel therapeutics for hemophilia including gene therapy.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-22-009-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
|Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.|
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Dr. Steven Pipe has relevant financial relationships related to advisory activities from GeneVentiv Therapeutics and consulting from ApcinteX, now a Centessa Company, ASC Therapeutics, Bayer AG, BioMarin Pharmaceutical Inc., Catalyst Biosciences, CSL Behring, Freeline, Genentech - A Member of the Roche Group, GeneVentiv Therapeutics, HEMA Biologics, LLC, Intellia Therapeutics, Inc., Novo Nordisk A/S, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sangamo Therapeutics, Sanofi, Spark Therapeutics, Inc., Takeda Oncology, and uniQure N.V. He has received research grant(s) from Siemens.
All of the relevant financial relationships listed for this individual have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from CSL Behring, LLC.
©2022 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Please use the box in the top-right corner of the screen to login or register.